ZOLL’s TherOx SuperSaturated Oxygen Therapy to Be Highlighted at SCAI Shock Virtual Conference

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx^® SuperSaturated Oxygen (SSO₂) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.

The panel discussion, which will be moderated by Babar Basir, D.O., FSCAI (Henry Ford Health System, MI), will take place on Friday, October 8, from 9 to 10 a.m. EDT and will delve into SSO₂ Therapy, specifically addressing its FDA-approved indications, clinical data supporting use in STEMI case studies, and an upcoming IDE trial in cardiogenic shock. Presenters include:

• Gregg W. Stone, M.D., FACC, MSCAI (Ichan School of Medicine at Mount Sinai, New York)
• Steven J. Yakubov, M.D., MSCAI (Ohio Health Heart & Vascular Physicians, OH)
• J. Richard Spears, M.D. FACC (Beaumont Hospital, MI)

“We are thrilled to have these key thought leaders at SCAI Shock examine and discuss SSO₂ Therapy and share their real-world experiences,” said Neil Johnston, President of ZOLL Circulation.

SCAI Shock’s goal is to break the 50 percent mortality barrier of cardiogenic shock by bringing together global experts from the fields of interventional cardiology, advanced heart failure, emergency medicine, cardiac critical care, and cardiac surgery to discuss cardiogenic shock, its treatment and new science and technologies.

SuperSaturated Oxygen (SSO₂) Therapy is the first and only FDA-approved treatment to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention. SSO₂ Therapy delivers levels of dissolved oxygen at 7-10 times the normal amount directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting and has been shown in multiple randomized prospective clinical trials to consistently and safely reduce damage and scarring (infarct size) in heart attack patients.¹ It is currently indicated for patients who suffer left anterior descending ST-elevation myocardial infarction (LAD STEMI) – also known as widowmaker heart attacks due to the high mortality rate – and are treated within six hours of symptom onset.

SSO₂ Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL.

About ZOLL

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 40,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.

Copyright © 2021 ZOLL Medical Corporation. TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

¹ Stone, G.W. et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016;67(14):1674–83.

Media:
Matt Hogan
ZOLL Medical Corporation
978-805-6561
media@zoll.com